Detalhe da pesquisa
1.
[Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department].
Gan To Kagaku Ryoho
; 38(13): 2579-84, 2011 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-22189222
2.
[Prediction of treatment efficacy by the M-protein reduction rate after the first cycle of VAD therapy for multiple myeloma].
Rinsho Ketsueki
; 51(8): 685-9, 2010 Aug.
Artigo
em Japonês
| MEDLINE | ID: mdl-20805676
3.
p53 mutations and tetraploids under r- and K-selection.
Oncogene
; 21(19): 3043-9, 2002 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12082535
4.
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.
Int J Hematol
; 93(5): 618-623, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21523339
5.
Ex vivo simulation of the action of antileukemia drugs by measuring apoptosis-related mRNA in blood.
Clin Chem
; 54(4): 673-81, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18292124
6.
ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
Mod Pathol
; 16(8): 828-32, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12920229